{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:31:55Z","timestamp":1792801915845,"version":"4.5.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Pfizer, Inc."}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.vaccine.2019.08.048","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T17:47:21Z","timestamp":1567705641000},"page":"6201-6207","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":99,"title":["Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults"],"prefix":"10.1016","volume":"37","author":[{"given":"Allison","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Lamberth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Severs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Scully","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanela","family":"Tarabar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ginis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathrin U.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Gruber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.08.048_b0005","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0140-6736(09)61204-6","article-title":"Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates","volume":"374","author":"O'Brien","year":"2009","journal-title":"Lancet"},{"issue":"Suppl 5","key":"10.1016\/j.vaccine.2019.08.048_b0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/1469-0691.12461","article-title":"Pneumococcal infection in adults: burden of disease","volume":"20","author":"Drijkoningen","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.vaccine.2019.08.048_b0015","unstructured":"Wahl B. Global burden of Streptococcus pneumoniae in children younger than 5 years in the era of pneumococcal conjugate vaccines (PCV): 2000-2015. In: 10th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-10). Glasgow, Scotland; 2016."},{"key":"10.1016\/j.vaccine.2019.08.048_b0020","unstructured":"Centers for Disease Control and Prevention. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Streptococcus pneumoniae; 2016. Available at: http:\/\/www.cdc.gov\/abcs\/reports-findings\/survreports\/spneu16.pdf [accessed 18.12.18]."},{"key":"10.1016\/j.vaccine.2019.08.048_b0025","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1473-3099(17)30396-1","article-title":"Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015","volume":"17","author":"Troeger","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198772","article-title":"Global etiology of bacterial meningitis: A systematic review and meta-analysis","volume":"13","author":"Oordt-Speets","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.048_b0035","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1016\/j.vaccine.2011.02.088","article-title":"Healthcare utilization and cost of pneumococcal disease in the United States","volume":"29","author":"Huang","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jinf.2013.03.003","article-title":"Can an etiologic agent be identified in adults who are hospitalized for community-acquired pneumonia: Results of a one-year study","volume":"67","author":"Musher","year":"2013","journal-title":"J Infect"},{"key":"10.1016\/j.vaccine.2019.08.048_b0045","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1378\/chest.07-1456","article-title":"A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU","volume":"133","author":"Restrepo","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.vaccine.2019.08.048_b0050","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1093\/infdis\/jit506","article-title":"Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged >\/=50 years with community-acquired pneumonia","volume":"208","author":"Sherwin","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0055","doi-asserted-by":"crossref","first-page":"6802","DOI":"10.1016\/j.vaccine.2012.09.019","article-title":"Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales","volume":"30","author":"Andrews","year":"2012","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1586\/14760584.2015.963058","article-title":"Age-related immune response to pneumococcal polysaccharide vaccination: lessons for the clinic","volume":"14","author":"Iyer","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2019.08.048_b0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJM199111213252101","article-title":"The protective efficacy of polyvalent pneumococcal polysaccharide vaccine","volume":"325","author":"Shapiro","year":"1991","journal-title":"New England J Med"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2019.08.048_b0070","doi-asserted-by":"crossref","first-page":"S49","DOI":"10.1093\/infdis\/165-Supplement_1-S49","article-title":"Thymus-independent and thymus-dependent responses to polysaccharide antigens","volume":"165","author":"Stein","year":"1992","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/S0264-410X(03)00521-8","article-title":"Revaccination with the 23-valent pneumococcal polysaccharide vaccine in middle-aged and elderly persons previously treated for pneumonia","volume":"22","author":"Torling","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0080","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1086\/592691","article-title":"Pneumococcal vaccination of elderly adults: new paradigms for protection","volume":"47","author":"Jackson","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0085","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1016\/j.vaccine.2013.04.084","article-title":"Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0090","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1086\/648593","article-title":"Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine","volume":"201","author":"Pilishvili","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0095","unstructured":"Systematic Reviews: CRD's guidance for undertaking reviews in health care. University of York: Centre for Reviews and Dissemination; 2009. Available at: https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf [accessed 22.07.18]."},{"key":"10.1016\/j.vaccine.2019.08.048_b0100","first-page":"822","article-title":"Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged >\/=65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"63","author":"Tomczyk","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2019.08.048_b0105","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/cid\/ciu006","article-title":"Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children","volume":"58","author":"Angoulvant","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0110","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1016\/j.vaccine.2016.07.038","article-title":"Impact of PCV7\/PCV13 introduction on invasive pneumococcal disease (IPD) in young children: Comparison between meningitis and non-meningitis IPD","volume":"34","author":"Ben-Shimol","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0115","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1016\/j.vaccine.2015.06.062","article-title":"Impact of PCV7\/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years","volume":"33","author":"Greenberg","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0120","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/cid\/ciu524","article-title":"Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality","volume":"59","author":"Harboe","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039150","article-title":"Effect of serotype on focus and mortality of invasive pneumococcal disease: coverage of different vaccines and insight into non-vaccine serotypes","volume":"7","author":"van Hoek","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2019.08.048_b0130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1473-3099(05)70083-9","article-title":"Epidemiological differences among pneumococcal serotypes","volume":"5","author":"Hausdorff","year":"2005","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0135","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.1128\/AAC.03344-14","article-title":"Changes in pneumococcal serotypes and antimicrobial resistance after introduction of the 13-valent conjugate vaccine in the United States","volume":"58","author":"Richter","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.vaccine.2019.08.048_b0140","doi-asserted-by":"crossref","first-page":"6178","DOI":"10.1016\/j.vaccine.2015.10.015","article-title":"Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children","volume":"33","author":"Varon","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/21645515.2015.1116654","article-title":"The multifaceted impact of pneumococcal conjugate vaccine implementation in children in France between 2001 to 2014","volume":"12","author":"Cohen","year":"2016","journal-title":"Human Vaccines Immunotherap"},{"key":"10.1016\/j.vaccine.2019.08.048_b0150","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1093\/cid\/ciw067","article-title":"Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine","volume":"62","author":"Tomczyk","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0155","doi-asserted-by":"crossref","first-page":"7207","DOI":"10.1016\/j.vaccine.2011.06.056","article-title":"The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A","volume":"29","author":"Cooper","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0160","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1016\/j.vaccine.2013.04.085","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults","volume":"31","author":"Jackson","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.08.048_b0165","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00128-18","article-title":"Development and validation of 13-plex Luminex-based assay for measuring human serum antibodies to Streptococcus pneumoniae capsular polysaccharides","volume":"3","author":"Pavliakova","year":"2018","journal-title":"mSphere"},{"key":"10.1016\/j.vaccine.2019.08.048_b0170","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s10096-014-2208-6","article-title":"Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?","volume":"34","author":"Torres","year":"2015","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0175","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1097\/INF.0000000000000849","article-title":"Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia","volume":"34","author":"Desai","year":"2015","journal-title":"Pediat Infect Disease J"},{"key":"10.1016\/j.vaccine.2019.08.048_b0180","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/cid\/cix647","article-title":"Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality","volume":"65","author":"Ramirez","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0185","unstructured":"United States Census Bureau. Quick facts; 2017. Available at: https:\/\/www.census.gov\/quickfacts\/fact\/table\/US\/PST045217 [accessed 18.12.18]."},{"key":"10.1016\/j.vaccine.2019.08.048_b0190","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa1408544","article-title":"Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults","volume":"372","author":"Bonten","year":"2015","journal-title":"New England J Med"},{"key":"10.1016\/j.vaccine.2019.08.048_b0195","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/cid\/ciy312","article-title":"Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design","volume":"67","author":"McLaughlin","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.08.048_b0200","doi-asserted-by":"crossref","first-page":"5854","DOI":"10.1016\/j.vaccine.2015.08.080","article-title":"Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18\u201349 years of age, naive to 23-valent pneumococcal polysaccharide vaccine","volume":"33","author":"Bryant","year":"2015","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19311120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:34:49Z","timestamp":1759401289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19311120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":40,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0264410X19311120"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1 trial of a 20-valent pneumococcal conjugate vaccine in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.08.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}